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Hyperglycaemia-induced oxidative stress  
in gestational diabetes mellitus (GDM)
Stres oksydacyjny indukowany hiperglikemią w cukrzycy ciążowej (GDM)
ABSTRACT
An imbalance between production of reactive oxygen 
species (ROS) and their clearance by antioxidant de-
fence mechanisms results in the development of oxida-
tive stress. Biological consequences of this state involve 
oxidative damage of key cellular components such as 
nucleic acids, lipids, or proteins and, in turn, impair-
ment of cell and tissue function. Evidence from clinical 
and experimental studies supports the notion that 
oxidative stress is one of pathologic factors associated 
with gestational diabetes mellitus (GDM), metabolic 
disorder defined as any degree of glucose intolerance 
with onset or first recognition during pregnancy. It 
has been established that high blood glucose concen-
trations in diabetic pregnancy induce oxidative stress 
by several mechanisms, including an enhanced ROS 
production in mitochondria, the polyol pathway and 
the hexosamine pathway, as well as protein kinase C 
(PKC) activation and an advanced glycation end-prod-
ucts (AGEs) formation, and changes in biomarkers of 
free radical-induced damage and antioxidant defences 
have been detected in maternal diabetes. Moreover, 
hyperglycaemia-induced oxidative stress is related 
with some congenital anomalies in diabetic pregnancy. 
The current article provides an overview how oxida-
tive stress is related to GDM, with special emphasis 
on the involvement of the hyperglycaemia-induced 
mechanisms in ROS overproduction, followed by dis-
cussion of indicators of oxidative stress. In addition, the 
relationship between oxidative stress and congenital 
malformations in diabetic pregnancy is described. 
(Diabet. Klin. 2015; 4, 5: 189–198)
Key words: biomarker; gestational diabetes mellitus 
(GDM); oxidative stress; reactive oxygen species 
(ROS)
STRESZCZENIE
Brak równowagi między produkcją reaktywnych form 
tlenu (ROS) a ich usunięciem przez antyoksydacyjne 
mechanizmy obronne prowadzi do rozwoju stresu ok-
sydacyjnego. Biologicznymi konsekwencjami tego sta-
nu są oksydacyjne uszkodzenia kluczowych składników 
komórkowych, takich jak kwasy nukleinowe, białka lub 
lipidy, które prowadzą do upośledzenia funkcji komó-
rek i tkanek. Dowody pochodzące z badań klinicznych 
i eksperymentalnych popierają koncepcję, że stres 
oksydacyjny jest jednym z patologicznych czynników 
związanych z cukrzycą ciążową (GDM), definiowaną 
jako różny stopień zaburzeń tolerancji węglowodanów 
po raz pierwszy rozpoznany lub rozwijający się pod-
czas ciąży. Ustalono, że wysokie stężenia glukozy we 
krwi kobiet z GDM indukują stres oksydacyjny poprzez 
kilka mechanizmów, w tym zwiększoną produkcję ROS 
w mitochondriach, szlak poliolowy, szlak heksozoami-
ny, aktywację kinazy białkowej C (PKC) oraz tworzenie 
końcowych produktów zaawansowanej glikacji (AGEs). 
Zmiany zarówno w biomarkerach uszkodzeń oksydacyj-
nych, jak i antyoksydacyjnym systemie obronnym były 
wykryte u pacjentek z GDM. Ponadto stres oksydacyjny 
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indukowany hiperglikemią w GDM jest związany z roz-
wojem wad wrodzonych płodu.
Niniejszy artykuł stanowi podsumowanie wiedzy 
o związku stresu oksydacyjnego z cukrzycą ciążową, 
ze szczególnym podkreśleniem udziału mechanizmów 
indukowanych hiperglikemią, które prowadzą do nad-
produkcji ROS, oraz omówieniem wskaźników stresu 
oksydacyjnego. Opisano także związek między stresem 
oksydacyjnym a występowaniem wad wrodzonych 
płodu podczas cukrzycy w ciąży. (Diabet. Klin. 2015; 
4, 5: 189–198)
Słowa kluczowe: biomarker, cukrzyca ciążowa 
(GDM), stres oksydacyjny, reaktywne formy tlenu (ROS)
Introduction
Gestational diabetes mellitus (GDM), defined as 
hyperglycaemia with onset or first recognition during 
pregnancy, is one of the most common metabolic dis-
orders occurring during pregnancy that affects from 3% 
to 34% of all pregnancies, depending on the screen-
ing criteria and ethnic group [1, 2]. Although GDM 
symptoms resolve after delivery, it has negative conse-
quences for both mother (e.g. preeclampsia, preterm 
delivery, caesarean section, elevated risk of developing 
type 2 diabetes mellitus and cardiovascular disease after 
pregnancy) and child (e.g. prematurity, macrosomia, 
hypoglycaemia, polycythaemia, and hypocalcaemia) 
[3]. Insulin resistance and b cells dysfunction are be-
lieved to be two major contributors to the pathogenesis 
of GDM. Although the precise mechanisms underlying 
these abnormalities are not fully understood so far, 
disturbances in the insulin signalling pathway [4, 5] 
and changes in plasma adipokine levels [6], as well 
as enhancement in inflammation [7, 8] and oxidative 
stress [9, 10] have been demonstrated.
Reactive oxygen species (ROS), including either 
oxygen radicals such as the hydroxyl radical (•OH), 
peroxyl radical (ROO•), the superoxide anion radical 
(O2
•–), or reactive non-radicals like hydrogen perox-
ide (H2O2) or singlet oxygen (
1O2), are highly reactive 
molecules generated within the cell predominantly as 
by-products of aerobic respiration and metabolism, 
which paradoxically can act as a double-edged sword 
in modulating human physiology. ROS function as 
second messengers in mammalian cells to regulate 
signal transduction cascades engaged in cell function, 
growth, differentiation and death as well as cytokine 
formation, and angiogenesis [11]. On the other hand, 
excessive ROS production can attenuate endogenous 
antioxidant systems leading to oxidative stress, which 
have detrimental effects on cellular DNA, protein and 
lipids. Oxidative damage of these biomolecules has 
been implicated in the pathology and complications 
of numerous diseases such as cancer, cardiovascular 
diseases, ischaemic diseases, aging processes and dia-
betes including GDM. 
Pregnancy per se is a condition associated with 
enhanced oxidative stress since the high metabolic de-
mand and elevated requirements of oxygen contributes 
to increased ROS production in the mitochondria of 
placenta, thought to be a major source of free radicals 
at onset of pregnancy and during labour. However, this 
state is balanced by adequate antioxidant responses. In 
GDM, when antioxidant defence is impaired then oxi-
dative damage increases. Hyperglycaemia has been 
directly implicated in the formation of free radicals by 
the mitochondrial electron-transport chain, enhanced 
polyol and hexosamine pathway flux, activation of 
protein kinase C (PKC), and augmented formation of 
advanced glycation end-products (AGEs) [10]. Moreo-
ver, hyperglycaemia-induced oxidative stress has been 
suggested to play an important role in the aetiology of 
several congenital anomalies in diabetic pregnancy [12].
In this review we will summarize the current per-
spective on how hyperglycaemia induces oxidative 
stress in GDM and how hyperglycaemia-induced oxida-
tive stress is connected to congenital malformations in 
diabetic pregnancy.
Hyperglycaemia-induced oxidative stress 
Several mechanisms underlying hyperglycaemia-in-
duced oxidative stress during GDM have been proposed 
so far. High glucose can disrupt the electron transport 
chain in mitochondria, resulting in the O2
•– overproduc-
tion. Additionally, ROS can be generated through the 
hexosamine, polyol and PKC pathways as well as in the 
process of AGEs formation (Fig. 1) [10].
The hexosamine pathway
The hyperglycaemia-induced hexosamine 
pathway begins with the rate-limiting enzyme 
glutamine:fructose-6-phosphate amidotransferase 
(GFAT) that converts fructose-6-phosphate into 
glucosamine-6-phosphate (Fig. 1.4). In turn, the glu-
cosamine-6-phosphate inhibits glucose-6-phosphate 
dehydrogenase (G6PD), the rate-limiting enzyme of the 
pentose phosphate pathway that generates NADPH. 
Hence, the enhanced hexosamine pathway lowers 
NADPH concentration leading to a reduction of glu-
tathione (GSH) level and increased oxidative stress [13]. 
The end-product of the hexosamine pathway is uridine 
diphosphate N-acetylglucosamine (UDP-Glc-NAc), the 
substrate for N- and O-glycosylation of numerous cel-
lular proteins including transcriptional factors [14]. 
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The relationship of the hexosamine pathway with 
insulin resistance has been established. Indeed, the 
O-linked N-acetylglucosamine modification of insulin 
receptor substrates 1 and 2 (IRS-1 and IRS-2) has been 
demonstrated to regulate the post-receptor insulin 
signalling involved in glucose transport and glycogen 
storage [15]. Additionally, several studies have revealed 
that GFAT overexpression in fat and liver causes insulin 
resistance and deterioration of the b-cell function [16–
18]. Moreover, glucosamine increases the plasminogen 
activator inhibitor-1 (PAI-1) promoter activity, affecting 
the development of microvascular diabetic complica-
tions such as diabetic nephropathy [14].
The polyol pathway
Under normal conditions, only approx. 3% of cellu-
lar glucose is converted into sorbitol in the polyol path-
way, whereas under hyperglycaemic condition approx. 
30% of glucose is metabolized in this pathway [19]. 
The first step of this pathway includes a reduction of 
glucose to sorbitol by aldose reductase (AR) that utilizes 
NADPH (Fig. 1.1 and Fig. 2). In the second step, sorbitol 
dehydrogenase (SDH) catalyses oxidation of sorbitol 
to fructose with concomitant NADH production. The 
polyol pathway participates in hyperglycaemia-induced 
oxidative stress by three mechanisms [20]. First, the AR 
competes with glutathione reductase (GR) for NADPH 
as a co-factor, thereby the GSH concentration decreases 
and the cellular antioxidant capacity impairs. Second, 
an enhanced SDH activity augments the NADH concen-
tration, the substrate for the NADPH-dependent oxidase 
(NOX), leading to superoxide anion overproduction. 
Third, fructose can be converted into fructose-3-phos-
phate (F-3-P) and 3-deoxyglucosone (3-DG). Since both 
products are more potent nonenzymatic glycation 
agents than glucose, they can effectively form AGEs.
Maternal hyperglycaemia has been shown to 
cause a rise in sorbitol concentration in foetal tissue 
and AR activity in the lenses of diabetic rat foetuses 
[21, 22]. Alterations in the polyol pathway have also 
been found in diabetic complications such as cardio-
myopathy, neuropathy, nephropathy, and retinopathy 
[20]. Additionally, a linkage of the AR overexpression 
to atherosclerosis has been reported in diabetic mice 
Figure 1. The influence of altered carbohydrate metabolism on ROS production in GDM. High glucose concentration in blood 
activates polyol (1), hexosamine (4) and PKC pathways (5), as well as AGEs production (2). Moreover, glycolysis (3) is increased in 
the hyperglycaemic state. The enhancement of those pathways leads to higher ROS concentration. GFAT — glutamine:fructose-
-6-phosphate amidotransferase; Gln — glutamine; Glu — glutamic acid; NAD+/NADH — nicotinamide adenine dinucleotide; 
NOX — NAD(P)H oxidase; PKC — protein kinase C; TCA cycle — tricarboxylic acid cycle; UDP-Glc-NAc — uridine diphosphate 
N-acetylglucosamine
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[23, 24]. To prevent these abnormalities, AR inhibitors 
(ARI) such as sorbinil, fidarestat, and imirestat, among 
others, are currently being intensively studied [20].
PKC pathway
Due to enhanced glycolysis under hyperglycae-
mic conditions, glyceraldehyde 3-phosphate (G-3-P) 
overproduction leads to increased dihydroxyacetone 
phosphate (DHAP) formation. The reduction of DHAP to 
glycerol 3-phosphate followed by acylation generates 
diacylglycerol (DAG) [25]. In turn, an increased DAG 
concentration activates PKC, predominantly PKC-b, -d, 
and -a isoforms (Fig. 1.5). Hyperglycaemia-induced 
PKC activation has been detected in heart and superior 
mesenteric artery of diabetic mice [25, 26]. The relation-
ship between increased PKC pathway and enhanced 
oxidative stress has been suggested [25]. In fact, it has 
been shown that PKC-b inhibits endothelial NO synthase 
(eNOS) expression in endothelial cells [27], whereas 
PKC-a activates NOX5 leading to increased super oxide 
production [28]. Additionally, NOX-mediated ROS 
overproduction augments peroxynitrite formation and 
oxidation of tetrahydrobiopterin (BH4), eNOS co-factor, 
causing eNOS dysfunction through uncoupling its re-
ductase and oxygenase domains [29]. 
Advanced glycosylation end-products (AGEs) 
In diabetes, high glucose concentration increases 
the AGEs formation. The AGEs arise mainly from au-
toxidation of glucose to glyoxal, but also from decom-
position and fragmentation of the Amadori products 
(Fig. 1.2). First reaction in the production of AGEs is 
the condensation of the carbonyl group of glucose 
with a free amino group of a protein that results in 
the formation of a reversible Schiff base. Subsequently, 
the Schiff base can be converted into a covalently 
bound Amadori product followed by degradation to 
3-deoxyglucosone and methylglyoxal [30, 31]. These 
reactive dicarbonyl compounds react directly with 
amino groups of intracellular and extracellular protein 
forming AGEs. The AGEs cytotoxicity is a consequence 
of altered physiological function of specific proteins and 
cellular ROS production. The latter process is related 
with the activation of the type I cell surface receptor 
for AGEs (RAGE), belonging to the immunoglobulin 
superfamily, with subsequent induction of NOX [32]. 
The AGE-RAGE interaction also causes stimulation of 
some members of the mitogen-activated protein kinase 
(MAPK) family such as extracellular signal-regulated 
kinases (ERK)-1 and -2, and p38, resulting in activation 
of nuclear factor kB (NF-kB) and subsequently induction 
of the expression of adhesion molecules, cytokines and 
chemokines [33]. Pro-oxidant and pro-inflammatory 
functions of the AGE-RAGE axis have been implicated 
not only in the development and progression of diabetic 
micro- and macroangiopathy [33], but also in normal 
human labour accompanied by increased oxidative 
stress, formation of inflammatory mediators (e.g. cy-
tokines) and uterotonic phospholipid metabolites (e.g. 
prostaglandins) as well as in adverse pregnancy out-
comes. In support of this, AGEs significantly increases 
in vitro release of tumour necrosis factor-a (TNF-a), 
interleukin IL-1b, IL-6, IL-8, prostaglandin (PG)E2, PGF2a 
and 8-isoprostane from human placenta and gesta-
tional membranes with a concomitant increase in NF-kB 
p65 activation and ERK 1/2 phosphorylation [34], and 
concentrations of AGE-modified products in umbilical 
cord blood increase with gestation progression and 
Figure 2. Contribution of the polyol pathway to increased oxidative stress during hyperglycaemia. 3-DG — 3-deoxyglucosone; 
AGEs — advanced glycation end-products; AR — aldose reductase; F-3-P — fructose-3-phosphate; GR — glutathione reduc-
tase; GSH — reduced glutathione; GSSG — oxidized glutathione; NOX — NADPH oxidase; ROS — reactive oxygen species; 
SHD — sorbitol dehydrogenase
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in preeclampsia [35]. In regard to a relationship of 
AGEs with GDM, significantly higher serum AGE levels 
have been found in diabetic patients [36]. Moreover, 
increased AGE concentrations have been detected in 
GDM patients with foetal distress, foetal malformation 
and stillbirth compared with diabetic patients with 
normal foetal outcome, suggesting that AGEs may 
be an important risk factor for abnormal outcome in 
infants of GDMs [37]. 
Indicators of oxidative stress in GDM
Oxidative stress can trigger oxidative damage of 
essential cellular biomolecules such as DNA, proteins, 
and lipids (Fig. 3). Among lipid molecules present in 
cellular membrane, polyunsaturated fatty acids (PU-
FAs) are particularly ROS-sensitive since they contain 
double bonds between two carbon atoms that weaken 
neighbouring C-H bonds, thus facilitating a hydrogen 
atom removal during the attack of ROS [38]. Lipid 
peroxidation proceeds as a free radical mediated chain 
reaction resulting in the formation of several products 
such as lipid hydroperoxides (LOOHs), conjugated 
dienes, alkanes, aldehydes, and isoprostanes (Fig. 3). 
An increased LOOH level is a common indicator of 
oxidative stress [39]. The reactive end-products of lipid 
peroxidation such as malonyl dialdehyde (MDA) and 
4-hydroxy-2-nonenal (4-HNE) can readily react with 
cellular proteins and DNA, leading to the formation of 
stable adducts [40]. MDA can react with thiobarbituric 
acid yielding thiobarbituric acid reactive substances 
(TBARS), which are quantified to monitor lipid per-
oxidation. However, MDA is not specific for oxygen 
radical-induced lipid peroxidation since it can be also 
produced by cyclooxygenase in enzymatic lipid peroxi-
dation. Additionally, free-radical-catalysed peroxidation 
of arachidonic acid independent of cyclooxygenase 
results in formation of PGF2-like compounds, namely 
F2-isoprostanes. Among them, 8-iso-prostaglandin F2a 
(8-iso-PGF2a) is an important marker of endogenous 
lipid peroxidation [41]. The functional consequence of 
lipid peroxidation is an increase in membrane fluidity 
and permeability [38]. 
Among protein oxidative modifications, the ir-
reversible products are protein carbonyls (PCO) and 
3-nitrotyrosine (3-NT) (Fig. 3). Protein carbonyls are 
formed on several amino acids residues such as argi-
nine, histidine, lysine, proline, threonine and cysteine. 
Carbonylation may lead to AGEs formation, starting 
from condensation of amino group, predominantly at 
lysine and arginine side chains, and carbonyl generating 
N-glycoside that is transformed into the Schiff’s base 
and then the Amadori product [42]. The 3-NT is formed 
between reactive nitrogen species (RNS) and a protein’s 
tyrosine residue. 3-NT is thought to be a highly selective 
modification since not all tyrosine residues on a target 
protein can be nitrated [43]. The reversible protein 
oxidation includes cysteine modification products such 
as sulphenic acids, nitrosothiols, and s-glutathione. 
Cysteine is usually oxidized to sulphenic acid, which in 
turn can undergo S-nitrosylation (-SNO), S-glutathio-
nylation (protein-SSG), S-sulphenation (-SOH) or can 
be converted into disulphide (S-S-) [43]. These cysteine 
oxidative modifications are involved in redox regulation 
of protein functions through ROS and RNS.
Biomarkers of oxidative damage
In GDM, lipid peroxidation products are usually 
measured as indicators of oxidative stress. Numerous 
studies have revealed increased MDA and TBARS levels 
in maternal and cord blood as well as in placenta from 
pregnancies complicated by GDM (Tab. 1) [44–57]. Addi-
tionally, MDA level has been found to positively correlate 
Figure 3. Sources of ROS, antioxidant systems, and biological consequences of high ROS concentration
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with blood glucose concentration [40]. Besides MDA and 
TBARS, increased serum LOOHs concentration has also 
been detected in women with GDM (Tab. 1) [59–61]. 
Although there are limited data on protein oxida-
tion in GDM, several studies have demonstrated in-
creased levels of protein damage markers, including 
PCO, 3-NT, protein hydroperoxides (POOHs), and ad-
vanced oxidation protein products (AOPP), in plasma, 
serum, leukocytes, and placenta in GDM patients (Tab. 1) 
[9, 51, 62]. Moreover, the positive correlation between 
POOHs and glycated haemoglobin A1c (HbA1c) has been 
found in GDM women [62]. By contrast, decreased 
plasma 3-NT and LOOHs levels in GDM women at 
28 weeks of gestation has also been reported [58]. The 
reasons for that difference are uncertain, but may stem 
from a relatively small number of patients participating 
in this study. 
Endogenous antioxidants 
Endogenous enzymatic antioxidants such as su-
peroxide dismutase (SOD) that generates hydrogen 
peroxide from superoxide radicals and catalase (CAT) 
along with glutathione peroxidase (GPX) which decom-
pose hydrogen peroxide are believed to be the first line 
of defence against ROS propagation, oxidative stress 
and tissue damage in the organism. Therefore, these 
enzymes have been studied most frequently of the 
antioxidant systems during diabetic pregnancy so far 
(Fig. 3). It has been demonstrated that CAT activity is 
reduced in maternal cord plasma as well as in placenta 
of GDM women (Tab. 2) [53]. The SOD activity has been 
found to be generally decreased in GDM patients [44, 
56, 59, 63, 64], although there are also studies show-
ing its increased activity in cord blood and placenta 
of diabetic women (Tab. 2) [9, 53]. GPX activity has 
been reported to be decreased in cord blood [53] and 
unaltered in placenta of GDM women [9, 53]. It is im-
portant to note that the most significant differences 
in GPX activity have been seen in maternal blood. Dis-
crepancies among studies may arise from the variety of 
biological material analysed (i.e. whole blood, plasma, 
or erythrocytes), the different diagnostic GDM criteria 
and/or sample size used. 
Human studies on the importance of non-enzymatic 
antioxidants, i.e. tocopherol (vitamin E), ascorbate (vita-
min C), and carotenoids (vitamin A), in GDM are both 
contradictory and confusing [44, 50, 54, 55, 63–69]. 
The vitamin E concentration has been found to be in-
creased or decreased or unchanged by diabetes (Tab. 2). 
These inconsistencies may be partially explained by 
different diagnostic GDM criteria and small sample 
sizes. In the case of vitamin C, the majority of research 
has demonstrated its diminished plasma level in GDM 
women, but there is one study showing its increased 
serum level in GDM patients (Tab. 2) [44]. The vitamin 
A concentration has been generally found to be un-
changed in GDM patients, however, Suhail et al. [50] 
have revealed its reduced plasma concentration (Tab. 2). 
Oxidative stress and adverse outcomes  
in diabetic pregnancy 
The increased rate of foetal malformations in dia-
betic pregnancy is a major clinical issue, but the precise 
mechanisms underlying these changes currently remain 
poorly understood. Oxidative stress is considered as an 
important pathway by which diabetes may affect the 
normal development of the embryos. Early embryonic 
development is characterized by relative immaturity of 
antioxidant defence mechanisms, thus, predisposing 
the embryo to increased risk of ROS-induced oxidative 
damage of proteins, DNA, and lipid. In support of the 
significance of ROS in the embryonic maldevelop-
ment of diabetic pregnancy, the addition of SOD to 
“diabetic culture medium” containing high levels of 
glucose and ketone bodies has been shown to reduce 
hyperglycaemia-induced development anomalies in 
10.5-day-old rat embryos in culture [70]. Other anti-
oxidant enzymes or low-molecular-weight antioxidants 
added to the diet or in vitro have been also reported 
to diminish embryonic dysmorphogenesis in pregnant 
diabetic rats [71–73].
Among diabetic pregnancy-induced malforma-
tions, defects in neural tube and heart are the most 
commonly occurring [12, 74]. Studies on the role of 
genetic factors involved in the development of neural 
tube defects (NTDs) in a mouse model of diabetic em-
Table 1. Biomarkers of oxidative damage of lipids and 
proteins in GDM women
Biomolecule Biomarker References
Lipid ≠TBARS [44–47]
≠MDA [48–57]
≠LOOH [59–61]
ØLOOH [58]
≠8-isoprostanes [9, 26]
Protein ≠AOPP [51, 62]
≠POOH [62]
≠PCO [9, 62]
≠3-NT [62]
Ø3-NT [58]
≠increased; Ødecreased; 8-oxo-dG — 8-hydroxydeoxyguanosine; AOPP 
— advanced oxidation protein products; LOOH — lipid hydroperoxides; 
MDA — melanodialdehyde; 4-HNE — 4-hydroxy-2-nonenal; 8-iso-PGF2a 
— 8-iso-prostaglandin F2a; POOH — protein hydroperoxides; PCO — pro-
tein carbonyl; 3-NT — 3-nitrotyrosine
Iga A. Turek et al., Hyperglycaemia-induced oxidative stress in gestational diabetes mellitus (GDM)
195www.dk.viamedica.pl
bryopathy have revealed that NTDs are associated with 
deficient expression of Pax-3, the gene encoding a tran-
scription factor that is required for neural tube closure 
and that is expressed in neuroepithelium, neural crest, 
and somitic mesoderm [75]. Decreased Pax-3 expres-
sion appears to be involved in enhanced apoptosis, the 
central mechanism in the induction of diabetic embryo-
pathy, since apoptotic cells have been found at sites of 
neural tube defects in embryos carrying null mutation 
of the Pax-3 gene [75]. These findings indicate that 
the Pax-3 gene contributes to NTDs. Further studies in 
this field have disclosed that maternal hyperglycaemia 
increases the hypoxic state of the embryo, leading to 
inhibition of Pax-3 expression and increase of NTDs and 
this process is associated with increased oxidative stress 
[76]. Hence, diabetes-induced oxidative stress may also 
change embryonic gene expression, contributing to the 
embryonic damage.
Lately, new data have emerged connecting hypergly-
caemia-induced oxidative stress to inducible NOS (iNOS) 
up-regulation and nitrosative stress in diabetic NTDs. In 
this regard, it has been presented that suppression of 
oxidative stress with the use of both in vitro recom-
binant human soluble SOD (SOD1) treatment and in 
vivo SOD1 overexpression inhibited hyperglycaemia-in-
creased iNOS expression and consequent nitrosative 
stress along with apoptosis in diabetic embryopathy [77]. 
Congenital heart anomalies, including endocardial 
cushion (EC) defects, persistent truncus arteriosus (PTA) 
and ventricular septal defects (VSD), are one of the 
most common malformations in offspring of diabetic 
mothers, but their molecular basis remains obscure 
[74]. Recently, maternal diabetes-induced congenital 
heart defects have been demonstrated to associate 
with the ultrastructural changes, i.e. the presence of 
swollen mitochondria and disorganized myofilaments 
with poorly developed adherence junctions, in cardio-
myocytes of the ventricular wall as well as with the 
down-regulation of several genes, i.e. Bmp4, Msx1, and 
Pax3, involved in development of cardiac neural crest 
[78]. The role of oxidative stress in the cardiac defects 
in embryos of diabetic pregnancy has been proposed by 
Wang et al. [79] who have found that SOD1 overexpres-
sion in transgenic mice attenuates oxidative stress and 
Table 2. Antioxidant enzyme activities and vitamin concentrations in GDM
GDM/NGT GDM criteria Sample type CAT SOD GPX vit C vit A vit E Ref
Mother
16/27 Carpenter Erythrocytes ´ Ø ´ ´ [54]
20/20 O’Sullivan Erythrocytes ´ Ø [56]
59/60 WHO Erythrocytes/serum Ø ≠ ´ Ø [44]
18/18 ACOG Erythrocytes/plasma Ø ´ ´ [64]
23/23 ADA Plasma Ø Ø Ø [50]
13/13 ADA Plasma Ø ´ ´ [53]
53/25 NDDG Plasma Ø Ø Ø [59]
25/25 WHO Plasma Ø Ø [65]
20/20 O’Sullivan Plasma Ø Ø [66]
27/40 NDDG Plasma ≠ [67]
35/45 ADA Plasma ´ [69]
20/20 O’Sullivan Plasma/serum Ø ´ [63]
30/30 ACOG Serum ≠ [55]
10/12 Carpenter Serum ´ [68]
Cord & placenta
24/25 ADIPS Placenta ≠ ´ [9]
13/13 ADA Plasma Ø ≠ Ø [53]
Placenta Ø ´ ´
19/13 WHO Plasma Ø [57]
Placenta Ø
Placenta Ø
27/40 NDDG Plasma Ø [67]
≠increased; Ødecreased; ´ unchanged; ACOG — American College of Obstetricians and Gynaecologist; ADA — The American Diabetes Association; ADIPS 
— The Australian Diabetes in Pregnancy Society; Carpenter — Carpenter and Coustan criteria; NDDG — The National Diabetes Data Group; NGT — normal 
glucose tolerant women; O’Sullivan — O’Sullivan and Mahan criteria; WHO — World Health Organization
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reverses maternal hyperglycaemia-impaired signalling 
of transforming growth factor-b (TGF-b), which is es-
sential for cardiogenesis. 
Conclusions
GDM is a problem of great clinical importance 
underlying the development of numerous adverse 
maternal and perinatal outcomes. It is now generally 
accepted that an increased oxidative stress contributes 
to the pathogenesis of GDM and hyperglycaemia is 
a crucial factor that triggers this process through several 
mechanisms such as the polyol pathway, the hexosa-
mine pathway, PKC activation, AGEs formation, and 
the mitochondrial electron transport chain. Although 
alterations in biomarkers of oxidative stress have been 
found in GDM women, more experimental evidence is 
required to help resolve some controversies regarding 
levels of both antioxidant enzymes and non-enzymatic 
antioxidants in maternal and cord plasma, as well as 
in placenta. Moreover, there is still an urgent need to 
determine the precise molecular mechanisms underly-
ing the relationship between oxidative stress and major 
congenital malformations such as defects in neural tube 
and heart in diabetic pregnancy. 
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